Susquehanna Fundamental Investments LLC Makes New Investment in Emergent BioSolutions Inc. (NYSE:EBS)

Susquehanna Fundamental Investments LLC bought a new stake in Emergent BioSolutions Inc. (NYSE:EBS) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 98,731 shares of the biopharmaceutical company’s stock, valued at approximately $944,000. Susquehanna Fundamental Investments LLC owned 0.18% of Emergent BioSolutions as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Alpine Global Management LLC acquired a new stake in shares of Emergent BioSolutions in the fourth quarter worth approximately $112,000. Tower Research Capital LLC TRC grew its holdings in shares of Emergent BioSolutions by 7,075.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 16,576 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 16,345 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Emergent BioSolutions by 67.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock valued at $10,554,000 after buying an additional 444,790 shares during the last quarter. Jump Financial LLC lifted its stake in shares of Emergent BioSolutions by 279.3% in the fourth quarter. Jump Financial LLC now owns 141,938 shares of the biopharmaceutical company’s stock worth $1,357,000 after buying an additional 104,518 shares in the last quarter. Finally, Barclays PLC boosted its position in Emergent BioSolutions by 140.5% during the fourth quarter. Barclays PLC now owns 94,523 shares of the biopharmaceutical company’s stock worth $904,000 after acquiring an additional 55,215 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Insider Buying and Selling

In related news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the transaction, the director now owns 101,100 shares of the company’s stock, valued at approximately $589,413. This trade represents a 25.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

EBS has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, April 1st. StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th.

Emergent BioSolutions Price Performance

Shares of EBS stock opened at $5.14 on Friday. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The company has a market capitalization of $279.29 million, a PE ratio of -1.25 and a beta of 2.14. The firm’s 50-day moving average is $5.31 and its two-hundred day moving average is $8.05. Emergent BioSolutions Inc. has a 12 month low of $3.36 and a 12 month high of $15.10.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The firm had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. During the same period in the prior year, the firm posted ($0.77) earnings per share. Analysts predict that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current year.

Emergent BioSolutions declared that its board has initiated a stock buyback program on Monday, March 31st that permits the company to buyback $50.00 million in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire up to 19% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.